Over the last few years, evidence has piled up that psychedelic drugs can provide relatively rapid relief from the symptoms of clinical depression. The drugs seemingly work by boosting the brain's ability to remodel connections among neurons and incorporate new experiences. While we have a good picture of which proteins are responsible for the drug's hallucinogenic effects, we're still figuring out how those pathways plug into the brain's ability to change itself.
Those lingering uncertainties aren't standing in the way of people trying to develop potentially life-altering treatments. One of the big challenges is probably the hallucinations themselves, which can potentially incapacitate someone for hours after a treatment. But researchers have now described a study showing that the shortest-acting psychedelic, DMT, appears to be just as effective as the rest.
Fast-acting
DMT, or dimethyltryptamine, is probably best known as a key component of ayahuasca, a liquid made from a combination of two or more plants. The mixture is important because the body produces an enzyme that rapidly digests DMT, blocking its effects. The additional plants contain a chemical that inhibits this enzyme, providing a longer-lasting experience.
Read full article
Comments
Source: Ars Technica
